Binnopharm links up with Mabwell to launch joint production of MAb in Russia
Russian drugmaker Binnopharm Group together with China’s Mabwell (SHA: 688062) announced plans to localize the production of a monoclonal antibody (MAb)-based drug for the treatment of asthma and atopic dermatitis in Russia.
Currently, the drug Dupixent (dupilumab), which is priced at an average of 76,000 roubles ($1,000) per package, is supplied by France's Sanofi (Euronext; SAN), reports The Pharma Letter’s local correspondent.
Recently Russian media reported that Binnopharm has reached an agreement with Shanghai-based Mabwell to localize dupilumab in Russia. The drug is intended for the treatment of atopic dermatitis and bronchial asthma. According to the Russian state drug registry, one drug based on dupilumab is currently registered in Russia, Dupixent from Sanofi. The registry says that the drug's active ingredient is manufactured in Belgium and Ireland.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
| Headless Content Management with Blaze